Vizex Investments Ltd
financial consultations

Last news

Transenterix announces 1st US sale

Nov 13, 2017 14
November 13th. Transenterix Inc…

We no longer recommend Array Biopharma Inc

Nov 11, 2017 10
November 11th 2017. We are withdrawing…

Transenterix announces the first sale of the Senhance in Germany

February 23rd. 2017.  Transenterix announced that the Company has launched commercial operations and completed its first sale of the Senhance Surgical System in Germany.

St. Marien-Krankenhaus Siegen, a large multi-specialty hospital, has purchased the Senhance Surgical System to establish a robotic surgical program that will initially be focused on general and gynecologic surgery.

TransEnterix, Inc. Announces $5.2 million Investment by SOFAR S.p.A

January 5th 2017  TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, announced today that the Company has received an increased equity investment from SOFAR S.p.A("SOFAR"), valued at €5 million, or approximately $5.2 million.

TransEnterix Announces Distribution Agreement for Australia and New Zealand for Senhance Surgical Robotic System

November 8th 2016 TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it has expanded distribution of the Senhance™ Surgical Robotic System (the "Senhance"). TransEnterix has partnered with Getz Healthcare to be the exclusive distribution partner for the Senhance in the Australian and New Zealand markets.

Array biopharma announced Q1 results

November 2nd 2016.  Array Biopharma announced Q1 2016 results.  Important business updates included binimetinib (NEMO program) submission (with Pierre Fabre) for marketing approval to European Medicines Agency (European equivalent of US FDA). With that, NEMO program currently is under review for marketing approval in both the U.S. and the E.U. which will help to launch the marketing process in those largest markets at the same time.  Of the financial data notable was the company cash position as of October 3rd - $241M.  With all current programs fully funded by partners, and any other major costly new programs very unlikely, Array Biopharma is not expected to bear any major expences in the foreseeable future and already has enough cash to commercialize NEMO program after its approval by US FDA.

Вайзекс Инвестментс ООД © 2015 | Всички права запазени